Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Qutenza

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Qutenza. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-005872-41 Sponsor Protocol Number: QTZ-EC-0004 Start Date*: 2012-04-25
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study
    Medical condition: Patients who have a documented diagnosis of probable or definite Peripheral Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) FI (Completed) AT (Completed) SK (Completed) ES (Completed) BE (Completed) SI (Completed) GB (Completed) DE (Completed) GR (Completed) PT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-001586-32 Sponsor Protocol Number: GN12RE072 Start Date*: 2012-12-13
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: The role of Qutenza (topical capsaicin 8%) in the treatment of chronic pain from critical ischaemia in patients with end stage renal failure
    Medical condition: Chronic pain from critical limb ischaemia in patients with end-stage renal failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023258-34 Sponsor Protocol Number: QTZ-EC-0002 Start Date*: 2011-05-02
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: Tolerability of QUTENZA(TM) when applied after pre-treatment with lidocaine or tramadol in subjects with peripheral neuropathic pain – A randomized, multi-center, assessor-blinded study
    Medical condition: Documented diagnosis at the Treatment Visit of either: •PHN with pain persisting at least 3 months since shingles vesicle crusting, or •Post-traumatic Peripheral Neuropathic Pain syndrome, includin...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) IE (Completed) BE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002947-74 Sponsor Protocol Number: 1-12 Start Date*: 2013-07-19
    Sponsor Name:Medizinische Universität Wien
    Full Title: A prospective randomized, double blind, placebo-controlled, cross-over study to investigate the analgesic effect of Aspirin® to prevent the pain during the treatment with capsaicin patch 8% (Qutenza®)
    Medical condition: Qutenza is an approved product for the treatment of pain due to postherpetic neuralgia and peripheral neuropathies. Since its application is painful, it is often necessary to give analgesics or loc...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002266-71 Sponsor Protocol Number: GN14RE146 Start Date*: 2015-01-02
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: The role of Qutenza (topical capsaicin 8%) in treating neuropathic pain from arteriovenous fistulae in patients with end stage renal failure
    Medical condition: Chronic neuropathic pain from arteriovenous fistulae in patients with end stage renal failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001022-57 Sponsor Protocol Number: Qutenza-FM-20 Start Date*: 2020-12-18
    Sponsor Name:Wojciech Zbigniew Pawlak
    Full Title: The effect of Qutenza application in patients with post-operative neuropathic pain: A double-blind, randomized, controlled pilot study
    Medical condition: Post-operative neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004852 10054095 Neuropathic pain LLT
    20.0 100000004852 10077974 Peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016458-42 Sponsor Protocol Number: E05-CL-3002 Start Date*: 2011-10-20
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZA plus Standard of Care versus Standard of Care alone in Subjects with Painful Diabetic Peri...
    Medical condition: Painful Diabetic Peripheral Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10012683 Diabetic peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) CZ (Completed) NL (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016457-18 Sponsor Protocol Number: E05-CL-3001 Start Date*: 2010-07-20
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain
    Medical condition: Peripheral Neuropathic Pain in Postherpetic Neuralgia (PHN), Painful HIV-Associated Neuropathy (HIV-AN), Peripheral Neuropathic Injury (PNI), Idiopathic Small Nerve Neuropathy (ISNN) or other Perip...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) BE (Completed) GB (Completed) CZ (Completed) FI (Completed) ES (Completed) AT (Completed) IT (Completed) HU (Completed) NL (Completed) SK (Completed) PL (Completed) SI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001587-30 Sponsor Protocol Number: GU11SU387 Start Date*: 2013-09-26
    Sponsor Name:NHS Greater Glasgow and Clyde
    Full Title: The role of pre-emptive analgesia with Qutenza (topical capsaicin 8%) in preventing neuropathic pain following lower limb amputation: a pilot randomised controlled study
    Medical condition: Chronic neuropathic pain following limb amputation
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    16.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001409-64 Sponsor Protocol Number: AV001 Start Date*: 2021-09-16
    Sponsor Name:Averitas Pharma, Inc.
    Full Title: An interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial evaluating the efficacy and safety of Qutenza® in subjects with post-surgical neuropat...
    Medical condition: Post-surgical neuropathic pain (PSNP)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002264-25 Sponsor Protocol Number: Start Date*: 2011-10-12
    Sponsor Name:Medizinische Universität Wien,Univ.Klinik f.Anästhesie,Allgemeine Intensivmedizin u.Schmerztherapie
    Full Title: Cooling for reducing treatment-related pain when applying capsaicin 8% patch
    Medical condition: healthy volunteers
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002406-46 Sponsor Protocol Number: 13.06.2012 Start Date*: 2012-10-09
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie
    Full Title: Epidermal Nerve Fibre Density Reduction as a Function of Application Time of topical high-dose and low-dose Capsaicin
    Medical condition: Impact of Capsaicin on epidermal nerve fibres
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001312-59 Sponsor Protocol Number: CRO1824 Start Date*: 2011-06-24
    Sponsor Name:Imperial College London
    Full Title: A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remoduli...
    Medical condition: Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood pressure in the arteries to the lungs, rapidly evolving in a clinical syndrome of dyspnoea and f...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001420-35 Sponsor Protocol Number: LBP_Caps_v1 Start Date*: 2012-06-05
    Sponsor Name:Abteilung für Anästhesie, Intensiv- und Schmerzmedizin, Wilhelminenspital der Stadt Wien
    Full Title: The effect of a single skin treatment with Capsaicine 8% in low back pain
    Medical condition: chronic low back pain with neuropathic pain component or unclear neuropathic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004746-17 Sponsor Protocol Number: 17HH4283 Start Date*: 2018-03-05
    Sponsor Name:Joint Research Compliance Office, Imperial College London and Imperial College Healthcare NHS Trust
    Full Title: Pain relief with disease modification by Capsaicin 8% patch: a clinical study in Diabetic Peripheral Neuropathy
    Medical condition: Diabetic painful neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001540-22 Sponsor Protocol Number: 76122012 Start Date*: 2012-06-27
    Sponsor Name:Mads Werner
    Full Title: CAPSAICIN PATCH 8% FOR THE TREATMENT OF PERSISTENT PAIN AFTER INGUINAL HERNIOTOMY
    Medical condition: CHRONIC PAIN AFTER INGUINAL HERNIOTOMY
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10049475 Chronic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002546-36 Sponsor Protocol Number: CAPS2 Start Date*: 2013-10-01
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie
    Full Title: Heat-, Cold-, and Mechanical Painthresholds under exposition of high dose topical Capsaicin
    Medical condition: Pain
    Disease: Version SOC Term Classification Code Term Level
    16.0 10018065 - General disorders and administration site conditions 10003051 Application site pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003559-39 Sponsor Protocol Number: ICO-A-2018-10 Start Date*: 2018-12-11
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: multicentric Study , open, randomized, comparing the topical treatment by patch of capsaïcine with 8 % ( Qutenza) to the oral prégabaline treatment in the early treatment of the neuropathic pains a...
    Medical condition: men and /or women older than 18 years with breast cancer for which a surgical operation was realized.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003965-21 Sponsor Protocol Number: 20VADS04 Start Date*: 2021-01-11
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae Neuropathic Pain.
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003208-22 Sponsor Protocol Number: CaPsaPPP-01 Start Date*: 2015-11-06
    Sponsor Name:Wilhelminen hospital
    Full Title: Does a two-day pretreatment with capsaicin reduce postoperative hyperalgesia and pain in surgical patients A prospective, randomized, double-blind, placebo-controlled, parallel group, single-cente...
    Medical condition: postoperative secondary mechanical hyperalgesia and postoperative pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:19:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA